Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.64 |
| ▸ | MME | P08473 | 3/20 | 0.56 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.54 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.54 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.53 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.53 |
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
| ▸ | ACE | P12821 | 2/20 | 0.51 |
| ▸ | CPA1 | P15085 | 2/20 | 0.51 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.51 |
| ▸ | GNPAT | O15228 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17510189 | 1.00 | MMP2 (0.64) | MMP2MMEITGB3ITGA2BERAP2 | |
| SCHEMBL30688845 | 1.00 | MMP2 (0.64) | MMP2MMEITGB3ITGA2BERAP2 | |
| SCHEMBL1374146 | 1.00 | MMP2 (0.64) | MMP2MMEITGB3ITGA2BERAP2 | |
| SCHEMBL29531496 | 1.00 | MMP2 (0.64) | MMP2MMEITGB3ITGA2BERAP2 | |
| SCHEMBL1374145 | 1.00 | MMP2 (0.64) | MMP2MMEITGB3ITGA2BERAP2 | |
| Hydrochloric Acid SCHEMBL11183447 | 0.99 | MMP2 (0.63) | MMP2MMEITGB3ITGA2BERAP2 | |
| SCHEMBL29531290 | 0.97 | MMP2 (0.62) | MMP2MMEITGB3ITGA2BERAP2 | |
| SCHEMBL29689355 | 0.97 | MMP2 (0.62) | MMP2MMEITGB3ITGA2BERAP2 | |
| SCHEMBL29376846 | 0.97 | MMP2 (0.62) | MMP2MMEITGB3ITGA2BERAP2 | |
| SCHEMBL29539550 | 0.97 | MMP2 (0.62) | MMP2MMEITGB3ITGA2BERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| EP-3478121-A1 | METHOD FOR SAMPLING GINGIVAL METABOLITES | The Procter and Gamble Company (US) | 2019-05-08 | — | — | EP | claimed |
| CN-109414109-A | Method for sampling gums metabolin | 宝洁公司 | 2019-03-01 | — | — | CN | claimed |
| US-9964472-B2 | Methods for sampling gingival metabolites | THE PROCTER & GAMBLE COMPANY (US) | 2018-05-08 | — | — | US | claimed |
| US-20180003598-A1 | METHODS FOR SAMPLING GINGIVAL METABOLITES | THE PROCTER & GAMBLE COMPANY | 2018-01-04 | — | — | US | claimed |
| WO-2018005335-A1 | METHOD FOR SAMPLING GINGIVAL METABOLITES | THE PROCTER & GAMBLE COMPANY (US) | 2018-01-04 | — | — | WO | claimed |
| CN-106456633-A | Sugar metabolism improving agent | 三得利控股株式会社 | 2017-02-22 | — | — | CN | claimed |
| CN-106455664-A | Composition with high content of cyclic dipeptide | 三得利控股株式会社 | 2017-02-22 | — | — | CN | claimed |
| EP-3478121-A1 | METHOD FOR SAMPLING GINGIVAL METABOLITES | The Procter and Gamble Company (US) | 2019-05-08 | — | — | EP | disclosed |
| US-10267797-B2 | Detection of oral microbial virulence factors | THE PROCTER & GAMBLE COMPANY (US) | 2019-04-23 | — | — | US | disclosed |
| US-10156566-B2 | Detoxification of microbial virulence factors in oral cavity | THE PROCTER & GAMBLE COMPANY (US) | 2018-12-18 | — | — | US | disclosed |
| US-9970934-B2 | Detection of oral microbial virulence factors | THE PROCTER & GAMBLE COMPANY (US) | 2018-05-15 | — | — | US | disclosed |
| US-9964472-B2 | Methods for sampling gingival metabolites | THE PROCTER & GAMBLE COMPANY (US) | 2018-05-08 | — | — | US | disclosed |
| EP-3292215-A1 | DETOXIFICATION OF MICROBIAL VIRULENCE FACTORS IN ORAL CAVITY | The Procter and Gamble Company (US) | 2018-03-14 | — | — | EP | disclosed |
| WO-2016179561-A1 | DETOXIFICATION OF MICROBIAL VIRULENCE FACTORS IN ORAL CAVITY | THE PROCTER & GAMBLE COMPANY (US) | 2016-11-10 | — | — | WO | disclosed |
| US-20160327557-A1 | DETECTION OF ORAL MICROBIAL VIRULENCE FACTORS | THE PROCTER & GAMBLE COMPANY | 2016-11-10 | — | — | US | disclosed |
| EP-2794663-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | Angiochem Inc. (CA) | 2014-10-29 | — | — | EP | disclosed |
| WO-2010063124-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2010-06-10 | — | — | WO | disclosed |
| US-5346888-A | To inhibit graft rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1994-09-13 | — | — | US | disclosed |
| US-4256632-A | ANTICAREINOGENIC AGENTS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 1981-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10156566-B2 | Detoxification of microbial virulence factors in oral cavity | GSTM2, GSTA2, GSTA1 | MMP2 446/4885MME 918/4885ITGB3 3083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.